Abstracts

TREATMENT OF COVID-19 IN 22 B-CELL–DEPLETED PATIENTS

Anti-CD20 therapy is used to treat autoimmune and hematological diseases. An absent or delayed antibody response against SARS-CoV-2 puts patients at risk for a protracted and severe disease course. These patients may benefit from antibody-based therapy of which convalescent plasma (ConvP) is the most broadly available source. ConvP from donors with SARS-CoV-2 antibody titers was…

REMDESIVIR VERSUS STANDARD OF CARE FOR SEVERE COVID-19

Remdesivir (RDV), a direct-acting nucleotide pro-drug inhibitor of viral RNA-dependent RNA polymerases, was approved by the FDA for the treatment of hospitalized patients (pts) with COVID-19 infection and has been shown to shorten time to recovery and improve clinical outcomes in randomized clinical trials. We present the final Day 28 (D28) analysis of RDV vs…

ACUTE KIDNEY INJURY IN PATIENTS WITH MODERATE COVID-19 TREATED WITH RDV VERSUS SoC

Remdesivir (RDV), an RNA-dependent RNA polymerase inhibitor of SARS-CoV-2, and its intravenous formulation excipient, cyclodextrin, are renally cleared. We sought to characterize whether RDV was associated with worsening renal function in hospitalized patients with moderate COVID-19. We conducted an open-label, phase 3 trial (NCT04252664) involving hospitalized patients with confirmed SARS-CoV-2 infection, evidence of pulmonary infiltrates,…

SYMPTOM OUTCOME MEASURES FOR OUTPATIENT COVID-19 PHASE 3 TREATMENT TRIALS

Due to the substantial morbidity but low rates of hospitalization and death among outpatients with COVID-19, symptom outcome measures should be considered for primary efficacy assessment in phase 3 treatment trials. We analyzed potential measures utilizing the ACTIV-2 participant diary. Data from the first 95 participants in ACTIV-2 were included. All had symptomatic SARS-CoV-2 infection…